Credit Suisse Group reaffirmed their outperform rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Monday morning. They currently have a GBX 4,500 ($59.38) target price on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the stock. Societe Generale reaffirmed a buy rating and set a GBX 7,500 ($98.97) price target on shares of Shire PLC in a research note on Wednesday, July 12th. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a research note on Wednesday, July 19th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 6,000 ($79.18) price target on shares of Shire PLC in a research note on Monday, July 3rd. Jefferies Group LLC dropped their price target on shares of Shire PLC from GBX 5,600 ($73.90) to GBX 5,250 ($69.28) and set a buy rating on the stock in a research note on Monday, August 7th. Finally, Berenberg Bank reaffirmed a buy rating and set a GBX 6,000 ($79.18) price target on shares of Shire PLC in a research note on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Shire PLC has a consensus rating of Buy and an average price target of GBX 5,509.68 ($72.71).
TRADEMARK VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/11/02/shire-plcs-shp-outperform-rating-reiterated-at-credit-suisse-group.html.
In other Shire PLC news, insider Anne Minto purchased 190 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was acquired at an average cost of GBX 3,785 ($49.95) per share, with a total value of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov purchased 8,400 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was acquired at an average cost of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.